Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

Prior treatment

• Prior RHC with mPAP \>20 mmHg.
• Currently on a Food and Drug Administration (FDA)-approved pulmonary arterial hypertension (PAH) medication for the treatment of PAH.

Other illness

• Diagnosed with chronic obstructive pulmonary disease (CPFE with mild emphysema notwithstanding).

Lab values

• History of ischemic heart disease or left-sided myocardial dysfunction within 12 months of Screening, defined as left ventricular ejection fraction \<40% or pulmonary capillary wedge pressure \>15 mmHg.

Other

• Uncontrolled or untreated moderate to severe sleep apnea as determined by the patient's physician.
• Pulmonary embolism within the past 3 months.
• Any other clinical features that, in the opinion of the Investigator, might adversely affect interpretation of study data or study safety, or make the patient unsuitable for RHC or HRCT (e.g., pregnancy).

• Patient gives voluntary written informed consent to participate in the study and are capable of reading and understanding questionnaires or forms in English or Spanish.
• Patients with a diagnosis of ILD based on computed tomography imaging, including:
  • Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis
  • Connective tissue disease-associated ILD with forced vital capacity (FVC) \<70%
  • Hypersensitivity pneumonitis
  • Scleroderma-related ILD
  • Autoimmune ILD
  • Nonspecific interstitial pneumonia
  • Occupational lung disease
  • Combined pulmonary fibrosis and emphysema with mild emphysema on lung imaging as determined by the Investigator
• Patients must have at least 2 signs or symptoms suggestive of PH, as specified by the study protocol.